Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells

BMB Reports

Volumn 46, Issue 1, 2013, Pages 59-64

  Kim, Nam Hoon ^a   Park, Hyo Jung ^a   Oh, Mi Kyung ^a   Kim, In Sook ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Antiproliferation; Auranofin; MDA MB 231 cells; STAT3; Telomerase

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; AURANOFIN; GOLD; STAT3 PROTEIN; TELOMERASE;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; AURANOFIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GOLD; HUMANS; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TELOMERASE;

EID: 84874742657     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2013.46.1.123     Document Type: Article

References (28)

1. Komeda, S. and Casini, A. (2012) Next-generation anticancer metallodrugs. Curr. Top. Med. Chem. 12, 219-235.
2. Ott, I. and Gust, R. (2007) Non platinum metal complexes as anti-cancer drugs. Arch. Pharm. Chem. Life Sci. 340, 117-126.
3. Borg, G., Allander, E., Lund, B., Berg, E., Brodin, U., Pettersson, H. and Trang, L. (1988) Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J. Rheumatol. 15, 1747-1754.
4. Kean, W. F. and Kean, I. R. (2008) Clinical pharmacology of gold. Inflammopharmacology 16, 112-125.
5. Jeon, K. I., Byun, M. S. and Jue, D. M. (2003) Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp. Mol. Med. 35, 61-66.
6. Angelucci, F., Sayed, A. A., Williams, D. L., Boumis, G., Brunori, M., Dimastrogiovanni, D., Miele, A. E., Pauly, F. and Bellelli, A. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem. 284, 28977-28985.
7. Gromer, S., Arscott, L. D., Williams, C. H. Jr., Schirmer, R. H. and Becker, K. (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273, 20096-20101.
8. Mustacich, D. and Powis, G. (2000) Thioredoxin reductase. Biochem. J. 346(Pt 1), 1-8.
9. Biaglow, J. E. and Miller, R. A. (2005) The thioredoxin reductase/ thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther. 4, 6-13.
10. Powis, G. and Kirkpatrick, D. L. (2007) Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 7, 392-397.
11. Urig, S. and Becker, K. (2006) On the potential of thio redoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16, 452-465.
12. Rigobello, M. P., Scutari, G., Folda, A. and Bindoli, A. (2004) Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol. 67, 689-696.
13. Gandin, V., Fernandes, A. P., Rigobello, M. P., Dani, B., Sorrentino, F., Tisato, F., Bjornstedt, M., Bindoli, A., Sturaro, A., Rella, R. and Marzano, C. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101.
14. Kim, I. S., Jin, J. Y., Lee, I. H. and Park, S. J. (2004) Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br. J. Pharmacol. 142, 749-755.
15. Park, S. J. and Kim, I. S. (2005) The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol. 146, 506-513.
16. Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A. and Rigobello, M. P. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42, 872-881.
17. Tiekink, E. R. (2008) Anti-cancer potential of gold complexes. Inflammopharmacology 16, 138-142.
18. Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A. and Messori, L. (2010) Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev. 30, 550-580.
19. Hirano, T., Ishihara, K. and Hibi, M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2556.
20. Chen, Z. and Han, Z. C. (2008) STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev. 28, 185-200.
21. Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A. and Jove, R. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.
22. Su, F., Ren, F., Rong, Y., Wang, Y., Geng, Y., Feng, M., Ju, Y., Li, Y., Zhao, Z. J., Meng, K. and Chang, Z. (2012) Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 14, R38.
23. Konnikova, L., Simeone, M. C., Kruger, M. M., Kotecki, M. and Cochran, B. H. (2005) Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 65, 6516-6520.
24. Lavecchia, A., Di Giovanni, C. and Novellino, E. (2011) STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr. Med. Chem. 18, 2359-2375.
25. Kim, N. H., Lee, M. Y., Park, S. J., Choi, J. S., Oh, M. K. and Kim, I. S. (2007) Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122, 607-614.
26. Nakaya, A., Sagawa, M., Muto, A., Uchida, H., Ikeda, Y. and Kizaki, M. (2011) The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk. Res. 35, 243-249.
27. Dixit, D., Sharma, V., Ghosh, S., Koul, N., Mishra, P. K. and Sen, E. (2009) Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic. Biol. Med. 47, 364-374.
28. Watson, W. H., Heilman, J. M., Hughes, L. L. and Spielberger, J. C. (2008) Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem. Biophys. Res. Commun. 368, 832-836.